{"id":55397,"date":"2023-03-31T04:03:17","date_gmt":"2023-03-31T02:03:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/"},"modified":"2023-03-31T04:03:17","modified_gmt":"2023-03-31T02:03:17","slug":"nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/","title":{"rendered":"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business"},"content":{"rendered":"
\n

TOKYO & HILVERSUM, Netherlands & OSLO, Norway & MANNHEIM, Germany–(BUSINESS WIRE)–NEC Corporation (NEC, TOKYO: 6701) announced in 2019 that it would expand the application of its cutting-edge AI technologies to drug development, focusing on advanced therapy as part of enhancing its healthcare business. Subsequently, in order to advance AI-powered personalized treatment and beyond, NEC acquired Norway-based NEC OncoImmunity (NOI) that same year.\n<\/p>\n

<\/a><\/p>\n

\nToday, NEC and NOI announced that NOI will be realigned as a subsidiary of NEC Bio B.V. (NB) in Hilversum, Netherlands, a newly established wholly owned subsidiary of NEC. At the same time, NEC established another new company, NEC Bio Therapeutics (NBT) in Mannheim, Germany, also a subsidiary of NB.\n<\/p>\n

\nThe new structure will enable NEC to drive long-term growth. The main focus of NB will be to streamline all AI, drug research and development activities. While NOI will continue with its research activities, working on the frontiers of the intersection between drug research and AI technology, NBT will lead the clinical development and clinical strategy of the assets in the drug development pipeline.\n<\/p>\n

\nNEC Bio, along with NOI and NBT, will continue to work with various partners to facilitate pre-clinical and clinical development in the infectious disease and oncology fields.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJoseph Jasper
\n
j-jasper(at)nec.com\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TOKYO & HILVERSUM, Netherlands & OSLO, Norway & MANNHEIM, Germany–(BUSINESS WIRE)–NEC Corporation (NEC, TOKYO: 6701) announced in 2019 that it would expand the application of its cutting-edge AI technologies to drug development, focusing on advanced therapy as part of enhancing its healthcare business. Subsequently, in order to advance AI-powered personalized treatment and beyond, NEC acquired … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55397","6":"format-standard","7":"category-industry"},"yoast_head":"\nNEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TOKYO & HILVERSUM, Netherlands & OSLO, Norway & MANNHEIM, Germany–(BUSINESS WIRE)–NEC Corporation (NEC, TOKYO: 6701) announced in 2019 that it would expand the application of its cutting-edge AI technologies to drug development, focusing on advanced therapy as part of enhancing its healthcare business. Subsequently, in order to advance AI-powered personalized treatment and beyond, NEC acquired ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-31T02:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230330005853\/en\/668386\/21\/NEC_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business\",\"datePublished\":\"2023-03-31T02:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/\"},\"wordCount\":223,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005853\\\/en\\\/668386\\\/21\\\/NEC_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/\",\"name\":\"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005853\\\/en\\\/668386\\\/21\\\/NEC_Logo.jpg\",\"datePublished\":\"2023-03-31T02:03:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005853\\\/en\\\/668386\\\/21\\\/NEC_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230330005853\\\/en\\\/668386\\\/21\\\/NEC_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/","og_locale":"en_US","og_type":"article","og_title":"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business - Pharma Trend","og_description":"TOKYO & HILVERSUM, Netherlands & OSLO, Norway & MANNHEIM, Germany–(BUSINESS WIRE)–NEC Corporation (NEC, TOKYO: 6701) announced in 2019 that it would expand the application of its cutting-edge AI technologies to drug development, focusing on advanced therapy as part of enhancing its healthcare business. Subsequently, in order to advance AI-powered personalized treatment and beyond, NEC acquired ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-31T02:03:17+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230330005853\/en\/668386\/21\/NEC_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business","datePublished":"2023-03-31T02:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/"},"wordCount":223,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005853\/en\/668386\/21\/NEC_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/","url":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/","name":"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230330005853\/en\/668386\/21\/NEC_Logo.jpg","datePublished":"2023-03-31T02:03:17+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230330005853\/en\/668386\/21\/NEC_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230330005853\/en\/668386\/21\/NEC_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nec-establishes-subsidiaries-in-europe-for-strengthening-global-ai-drug-development-business\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55397"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55397\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}